gb-701

**GB-701** is a small molecule, new chemical entity in the discovery stage, being developed as a long-acting, sustained-release ocular formulation designed to inhibit **complement factor B** in the complement cascade. Its primary mechanism of action is as a complement factor B inhibitor, with the intent to block the alternative pathway of the complement system, which is implicated in the progression of diseases such as **geographic atrophy** (GA) and **dry age-related macular degeneration** (dry AMD). GB-701 is being developed via a strategic partnership between CalciMedica and Insilico Medicine, with previous originator organizations including GrayBug and InSilico Medicine. The drug is designed for intraocular delivery using microparticle depot and implant formulations with biodegradable polymers (such as PLGA), aiming for sustained and well-tolerated intraocular drug release[1][3][5][7].